{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:09:24Z","timestamp":1767773364747,"version":"3.33.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-092","2022-PUMCH-B-092","2022-PUMCH-B-092"],"award-info":[{"award-number":["2022-PUMCH-B-092","2022-PUMCH-B-092","2022-PUMCH-B-092"]}]},{"name":"Beijing Natural Science Foundation","award":["7232118","7232118","7232118"],"award-info":[{"award-number":["7232118","7232118","7232118"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03760-0","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:59:54Z","timestamp":1737727194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associated factors related to production of autoantibodies and dermo-epidermal separation in bullous pemphigoid"],"prefix":"10.1007","volume":"317","author":[{"given":"Liuyiyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yagang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3760_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2019.00636","volume":"10","author":"PS Tabatabaei-Panah","year":"2019","unstructured":"Tabatabaei-Panah PS, Moravvej H, Sadaf Z, Babaei H, Geranmayeh M, Hajmanouchehri S et al (2019) Proinflammatory cytokine gene polymorphisms in Bullous Pemphigoid. Front Immunol 10:636. https:\/\/doi.org\/10.3389\/fimmu.2019.00636","journal-title":"Front Immunol"},{"key":"3760_CR2","doi-asserted-by":"publisher","first-page":"37125","DOI":"10.1038\/srep37125","volume":"6","author":"AK Forsti","year":"2016","unstructured":"Forsti AK, Jokelainen J, Ansakorpi H, Seppanen A, Majamaa K, Timonen M, Tasanen K (2016) Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide Finnish Care Register study. Sci Rep 6:37125. https:\/\/doi.org\/10.1038\/srep37125","journal-title":"Sci Rep"},{"issue":"10","key":"3760_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/exd.13550","volume":"28","author":"K Natsuga","year":"2019","unstructured":"Natsuga K, Watanabe M, Nishie W, Shimizu H (2019) Life before and beyond blistering: the role of collagen XVII in epidermal physiology. Exp Dermatol 28(10):1135\u20131141. https:\/\/doi.org\/10.1111\/exd.13550","journal-title":"Exp Dermatol"},{"issue":"3 Pt B","key":"3760_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jid.2021.11.028","volume":"142","author":"Y Mai","year":"2022","unstructured":"Mai Y, Izumi K, Sawada K, Akasaka E, Mai S, Sawamura D et al (2022) A 1,035-Subject study suggesting a history of bone fracture as a possible factor Associated with the development of Anti-BP180 autoantibodies. J Invest Dermatol 142(3 Pt B):984\u2013987e983. https:\/\/doi.org\/10.1016\/j.jid.2021.11.028","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3760_CR5","doi-asserted-by":"publisher","first-page":"e10566","DOI":"10.1371\/journal.pone.0010566","volume":"5","author":"T Shimbo","year":"2010","unstructured":"Shimbo T, Tanemura A, Yamazaki T, Tamai K, Katayama I, Kaneda Y (2010) Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma. PLoS ONE 5(5):e10566. https:\/\/doi.org\/10.1371\/journal.pone.0010566","journal-title":"PLoS ONE"},{"issue":"3","key":"3760_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/antib11030044","volume":"11","author":"C Cole","year":"2022","unstructured":"Cole C, Borradori L, Amber KT (2022) Deciphering the contribution of BP230 autoantibodies in Bullous Pemphigoid. Antibodies 11(3):44. https:\/\/doi.org\/10.3390\/antib11030044","journal-title":"Antibodies"},{"issue":"4","key":"3760_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","volume":"307","author":"E Alpsoy","year":"2015","unstructured":"Alpsoy E, Akman-Karakas A, Uzun S (2015) Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res 307(4):291\u2013298. https:\/\/doi.org\/10.1007\/s00403-014-1531-1","journal-title":"Arch Dermatol Res"},{"key":"3760_CR8","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.lanwpc.2024.101216","volume":"52","author":"E Ma\u2019u","year":"2024","unstructured":"Ma\u2019u E, Cullum S, Mukadam N, Davis D, Rivera-Rodriguez C, Cheung G (2024) Estimating the incidence of dementia in New Zealand: a cohort study applying capture-recapture modelling to routinely collected linked health datasets. Lancet Reg Health West Pac 52:101216. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101216","journal-title":"Lancet Reg Health West Pac"},{"issue":"11","key":"3760_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/biology12111396","volume":"12","author":"R Agrawal","year":"2023","unstructured":"Agrawal R, Hu A, Bollag WB (2023) The skin and inflamm-aging. Biology (Basel) 12(11):1396. https:\/\/doi.org\/10.3390\/biology12111396","journal-title":"Biology (Basel)"},{"issue":"10","key":"3760_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","volume":"10","author":"F Moro","year":"2020","unstructured":"Moro F, Fania L, Sinagra JLM, Salemme A, Zenzo GD (2020) Bullous Pemphigoid: trigger and predisposing factors. Biomolecules 10(10):1432. https:\/\/doi.org\/10.3390\/biom10101432","journal-title":"Biomolecules"},{"key":"3760_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14389","author":"L Iyengar","year":"2024","unstructured":"Iyengar L, Hosking P, Dowsett J, Su J (2024) Expression of JAK\/STAT signalling in bullous pemphigoid. Australas J Dermatol:Advance Online Publication. https:\/\/doi.org\/10.1111\/ajd.14389","journal-title":"Australas J Dermatol:Advance Online Publication"},{"key":"3760_CR12","doi-asserted-by":"publisher","first-page":"2050313X2311609","DOI":"10.1177\/2050313x231160926","volume":"11","author":"LM Gresham","year":"2023","unstructured":"Gresham LM, Kirchhof MG (2023) A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report. SAGE Open Med Case Rep 11:2050313X231160926. https:\/\/doi.org\/10.1177\/2050313x231160926","journal-title":"SAGE Open Med Case Rep"},{"key":"3760_CR13","doi-asserted-by":"publisher","first-page":"110591","DOI":"10.1016\/j.intimp.2023.110591","volume":"122","author":"HD Li","year":"2023","unstructured":"Li HD, Wang HL, Qiao GZ, Liu YX, Zhang FR, Pan FT (2023) Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol 122:110591. https:\/\/doi.org\/10.1016\/j.intimp.2023.110591","journal-title":"Int Immunopharmacol"},{"issue":"46","key":"3760_CR14","doi-asserted-by":"publisher","first-page":"E6301","DOI":"10.1073\/pnas.1515386112","volume":"112","author":"M Xu","year":"2015","unstructured":"Xu M, Tchkonia T, Ding H, Ogrodnik M, Lubbers ER, Pirtskhalava T et al (2015) JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A 112(46):E6301\u20136310. https:\/\/doi.org\/10.1073\/pnas.1515386112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3760_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jare.2022.03.019","volume":"44","author":"M Belheouane","year":"2023","unstructured":"Belheouane M, Hermes BM, Van Beek N, Benoit S, Bernard P, Drenovska K et al (2023) Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. J Adv Res 44:71\u201379. https:\/\/doi.org\/10.1016\/j.jare.2022.03.019","journal-title":"J Adv Res"},{"key":"3760_CR16","doi-asserted-by":"publisher","first-page":"104331","DOI":"10.1016\/j.yexmp.2019.104331","volume":"112","author":"GL Scaglione","year":"2020","unstructured":"Scaglione GL, Fania L, De Paolis E, De Bonis M, Mazzanti C, Di Zenzo G et al (2020) Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: a pilot study. Exp Mol Pathol 112:104331. https:\/\/doi.org\/10.1016\/j.yexmp.2019.104331","journal-title":"Exp Mol Pathol"},{"key":"3760_CR17","doi-asserted-by":"publisher","first-page":"1212551","DOI":"10.3389\/fimmu.2023.1212551","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, van Beek N, Cepic A, Andreani NA, Chung CJ, Hermes BM et al (2023) The gut microbiome in bullous pemphigoid: implications of the gut-skin axis for disease susceptibility. Front Immunol 14:1212551. https:\/\/doi.org\/10.3389\/fimmu.2023.1212551","journal-title":"Front Immunol"},{"key":"3760_CR18","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3389\/fimmu.2019.02200","volume":"10","author":"J Russlies","year":"2019","unstructured":"Russlies J, Fahnrich A, Witte M, Yin JP, Benoit S, Glaser R et al (2019) Polymorphisms in the mitochondrial genome are Associated with Bullous Pemphigoid in germans. Front Immunol 10:2200. https:\/\/doi.org\/10.3389\/fimmu.2019.02200","journal-title":"Front Immunol"},{"key":"3760_CR19","doi-asserted-by":"publisher","first-page":"107231","DOI":"10.1016\/j.phrs.2024.107231","volume":"205","author":"M Olbrich","year":"2024","unstructured":"Olbrich M, Hartmann AM, K\u00fcnzel S, Aherrahrou Z, Schilf P, Baines JF et al (2024) Mitochondrial DNA variants and microbiota: an experimental strategy to identify novel therapeutic potential in chronic inflammatory diseases. Pharmacol Res 205:107231. https:\/\/doi.org\/10.1016\/j.phrs.2024.107231","journal-title":"Pharmacol Res"},{"issue":"8","key":"3760_CR20","doi-asserted-by":"publisher","first-page":"E535","DOI":"10.1111\/jdv.17285","volume":"35","author":"PS Tabatabaei-Panah","year":"2021","unstructured":"Tabatabaei-Panah PS, Moravvej H, Alirajab M, Arghand F, Babaei H, Didehvar E et al (2021) COL17A1 gene polymorphisms are frequent in bullous pemphigoid. JEADV 35(8):E535\u2013E538. https:\/\/doi.org\/10.1111\/jdv.17285","journal-title":"JEADV"},{"issue":"8","key":"3760_CR21","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.jid.2018.02.021","volume":"138","author":"Y Sun","year":"2018","unstructured":"Sun Y, Liu H, Wang Z, Fu X, Wang C, Mi Z et al (2018) The HLA-DQB1*03:01 is Associated with Bullous Pemphigoid in the Han Chinese Population. J Invest Dermatol 138(8):1874\u20131877. https:\/\/doi.org\/10.1016\/j.jid.2018.02.021","journal-title":"J Invest Dermatol"},{"key":"3760_CR22","doi-asserted-by":"publisher","first-page":"824110","DOI":"10.3389\/fimmu.2022.824110","volume":"13","author":"YM Wang","year":"2022","unstructured":"Wang YM, Mao XM, Liu YC, Yang YY, Jin HZ, Li L (2022) IL-13 genetic susceptibility to Bullous Pemphigoid: a potential target for treatment and a prognostic marker. Front Immunol 13:824110. https:\/\/doi.org\/10.3389\/fimmu.2022.824110","journal-title":"Front Immunol"},{"issue":"2","key":"3760_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/08820139.2020.1832113","volume":"51","author":"PS Tabatabaei-Panah","year":"2022","unstructured":"Tabatabaei-Panah PS, Moravvej H, Alirajab M, Etaaty A, Geranmayeh M, Hosseine F et al (2022) Association between TH2 cytokine gene polymorphisms and risk of Bullous Pemphigoid. Immunol Invest 51(2):343\u2013356. https:\/\/doi.org\/10.1080\/08820139.2020.1832113","journal-title":"Immunol Invest"},{"issue":"1","key":"3760_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2133.2005.06938.x","volume":"154","author":"YT Chang","year":"2006","unstructured":"Chang YT, Liu HN, Yu CW, Lin MW, Huang CH, Chen CC et al (2006) Cytokine gene polymorphisms in bullous pemphigoid in a Chinese population. Brit J Dermatol 154(1):79\u201384. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06938.x","journal-title":"Brit J Dermatol"},{"issue":"10","key":"3760_CR25","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00403-022-02386-4","volume":"315","author":"S Tukaj","year":"2023","unstructured":"Tukaj S, Bieber K, Pr\u00fc\u00dfmann W, Pr\u00fc\u00dfmann JN, Schmidt E, Zillikens D et al (2023) Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance. Arch Dermatol Res 315(10):2921\u20132926. https:\/\/doi.org\/10.1007\/s00403-022-02386-4","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"3760_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ced\/llad331","volume":"49","author":"R Maglie","year":"2024","unstructured":"Maglie R, Baffa ME, Senatore S, Pipit\u00f2 C, Caproni M, Solimani F, Antiga E (2024) Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease. Clin Exp Dermatol 49(2):161\u2013163. https:\/\/doi.org\/10.1093\/ced\/llad331","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"3760_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00403-018-1842-8","volume":"310","author":"M Rychlik-Sych","year":"2018","unstructured":"Rychlik-Sych M, Baranska M, Dudarewicz M, Skretkowicz J, Zebrowska A, Wozniacka A et al (2018) Haplotypes of ABCB1 1236C\u2009>\u2009T (rs1128503), 2677G\u2009>\u2009T\/A (rs2032582), and 3435C\u2009>\u2009T (rs1045642) in patients with bullous pemphigoid. Arch Dermatol Res 310(6):515\u2013522. https:\/\/doi.org\/10.1007\/s00403-018-1842-8","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"3760_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/jaut.1999.0345","volume":"14","author":"G Raux","year":"2000","unstructured":"Raux G, Gilbert D, Joly P, Daveau M, Martel P, Christ M, Tron F (2000) Association of KM genotype with bullous pemphigoid. J Autoimmun 14(1):79\u201382. https:\/\/doi.org\/10.1006\/jaut.1999.0345","journal-title":"J Autoimmun"},{"issue":"2","key":"3760_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000049183","volume":"18","author":"G Raux","year":"2001","unstructured":"Raux G, Gilbert D, Joly P, Martel P, Roujeau JC, Prost C et al (2001) IGHV3-associated restriction fragment length polymorphisms confer susceptibility to bullous pemphigoid. Exp Clin Immunogenet 18(2):59\u201366. https:\/\/doi.org\/10.1159\/000049183","journal-title":"Exp Clin Immunogenet"},{"key":"3760_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaut.2015.05.004","volume":"61","author":"A Recke","year":"2015","unstructured":"Recke A, Vidarsson G, Ludwig RJ, Freitag M, M\u00f6ller S, Vonthein R et al (2015) Allelic and copy-number variations of Fc\u03b3Rs affect granulocyte function and susceptibility for autoimmune blistering diseases. J Autoimmun 61:36\u201344. https:\/\/doi.org\/10.1016\/j.jaut.2015.05.004","journal-title":"J Autoimmun"},{"issue":"3","key":"3760_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00403-007-0755-8","volume":"299","author":"P Weisenseel","year":"2007","unstructured":"Weisenseel P, Martin S, Partscht K, Messer G, Prinz JC (2007) Relevance of the low-affinity type of the fc gamma-receptor IIIa-polymorphism in bullous pemphigoid. Arch Dermatol Res 299(3):163\u2013164. https:\/\/doi.org\/10.1007\/s00403-007-0755-8","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"3760_CR32","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jaad.2009.02.017","volume":"65","author":"A Guilabert","year":"2011","unstructured":"Guilabert A, Lozano F, Iranzo P, Suarez-Casasus B, Martinez-De Pablo I, Julia M, Mascaro JM (2011) A case of aggressive bullous pemphigoid associated with the defective functional variant of fc gamma receptor IIb: implications for pathogenesis? J Am Acad Dermatol 65(5):1062\u20131063. https:\/\/doi.org\/10.1016\/j.jaad.2009.02.017","journal-title":"J Am Acad Dermatol"},{"key":"3760_CR33","doi-asserted-by":"publisher","first-page":"1171802","DOI":"10.3389\/fmed.2023.1171802","volume":"10","author":"LY Kong","year":"2023","unstructured":"Kong LY, Huang DW, Lu JJ, Zhang YX, Li Y, Yi XM, Shi YL (2023) Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review. Front Med 10:1171802. https:\/\/doi.org\/10.3389\/fmed.2023.1171802","journal-title":"Front Med"},{"issue":"6","key":"3760_CR34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1046\/j.1365-2133.1998.02350.x","volume":"138","author":"CC Banfield","year":"1998","unstructured":"Banfield CC, Wojnarowska F, Allen J, George S, Venning VA, Welsh KI (1998) The association of HLA-DQ7 with bullous pemphigoid is restricted to men. Brit J Dermatol 138(6):1085\u20131090. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02350.x","journal-title":"Brit J Dermatol"},{"issue":"1","key":"3760_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13023-021-01863-9","volume":"16","author":"C Schwarm","year":"2021","unstructured":"Schwarm C, Gola D, Holtsche MM, Dieterich A, Bhandari A, Freitag M et al (2021) Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA105:05 and -DRB107:01, in germans. Orphanet J Rare Dis 16(1):228\u2013228. https:\/\/doi.org\/10.1186\/s13023-021-01863-9","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3760_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jdermsci.2017.11.014","volume":"89","author":"H Fang","year":"2018","unstructured":"Fang H, Shen SX, Zheng XD, Dang EL, Zhang JY, Shao S et al (2018) Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans. J Dermatol Sci 89(3):258\u2013262. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.11.014","journal-title":"J Dermatol Sci"},{"issue":"1","key":"3760_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5021\/ad.2018.30.1.8","volume":"30","author":"AA Chagury","year":"2018","unstructured":"Chagury AA, Sennes LU, Gil JM, Kalil J, Rodrigues H, Rosales CB, Miziara ID (2018) HLA-C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 alleles Associated to Bullous Pemphigoid in Brazilian Population. Ann Dermatol 30(1):8\u201312. https:\/\/doi.org\/10.5021\/ad.2018.30.1.8","journal-title":"Ann Dermatol"},{"key":"3760_CR38","doi-asserted-by":"publisher","first-page":"1050373","DOI":"10.3389\/fimmu.2022.1050373","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wang SH, Zuo YG (2022) Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Front Immunol 13:1050373. https:\/\/doi.org\/10.3389\/fimmu.2022.1050373","journal-title":"Front Immunol"},{"issue":"2","key":"3760_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3109\/15569527.2012.725444","volume":"32","author":"AS Karadag","year":"2013","unstructured":"Karadag AS, Bilgili SG, Calka O, Onder S, Kosem M, Burakgazi-Dalkilic E (2013) A case of levetiracetam induced bullous pemphigoid. Cutan Ocul Toxicol 32(2):176\u2013178. https:\/\/doi.org\/10.3109\/15569527.2012.725444","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"3760_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-4362.1997.tb03302.x","volume":"36","author":"J Miralles","year":"1997","unstructured":"Miralles J, Barnadas MA, Baselga E, Gelpi C, Rodriguez JL, deMoragas JM (1997) Bullous pemphigoid-like lesions induced by Amoxicillin. Int J Dermatol 36(1):42\u201347","journal-title":"Int J Dermatol"},{"issue":"3","key":"3760_CR41","first-page":"360","volume":"13","author":"C Warner","year":"2014","unstructured":"Warner C, Kwak Y, Glover M, Davis L (2014) Bullous pemphigoid induced by hydrochlorothiazide therapy. J Drugs Dermatol 13(3):360\u2013362","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"3760_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1046\/j.1365-2133.2000.03389.x","volume":"142","author":"M Ameen","year":"2000","unstructured":"Ameen M, Harman KE, Black MM (2000) Pemphigoid nodularis associated with nifedipine. Brit J Dermatol 142(3):575\u2013577. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03389.x","journal-title":"Brit J Dermatol"},{"issue":"2","key":"3760_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jaad.2010.02.032","volume":"65","author":"M Durdu","year":"2011","unstructured":"Durdu M, Baba M, Seckin D (2011) A case of bullous pemphigoid induced by aspirin. J Am Acad Dermatol 65(2):443\u2013444. https:\/\/doi.org\/10.1016\/j.jaad.2010.02.032","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3760_CR44","doi-asserted-by":"publisher","first-page":"E1202","DOI":"10.1097\/mjt.0000000000000283","volume":"23","author":"E Cozzani","year":"2016","unstructured":"Cozzani E, Chinazzo C, Burlando M, Romagnoli M, Parodi A (2016) Ciprofloxacin as a trigger for Bullous Pemphigoid: the second case in the literature. Am J Ther 23(5):E1202\u2013E1204. https:\/\/doi.org\/10.1097\/mjt.0000000000000283","journal-title":"Am J Ther"},{"issue":"11","key":"3760_CR45","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/archderm.141.11.1474-b","volume":"141","author":"LK Ferris","year":"2005","unstructured":"Ferris LK, Jukic D, English JC 3rd, Zirwas MJ (2005) Drug-induced bullous pemphigoid caused by a generic Canadian medication obtained over the internet. Arch Dermatol 141(11):1474\u20131476. https:\/\/doi.org\/10.1001\/archderm.141.11.1474-b","journal-title":"Arch Dermatol"},{"issue":"10","key":"3760_CR46","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","volume":"154","author":"KRB Kridin","year":"2018","unstructured":"Kridin KRB (2018) Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 inhibitors in patients with diabetes: estimating the risk of the New agents and characterizing the patients. JAMA Dermatol 154(10):1152\u20131158. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2352","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3760_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J Bene","year":"2016","unstructured":"Bene J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S et al (2016) Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance database. Brit J Dermatol 175(2):296\u2013301. https:\/\/doi.org\/10.1111\/bjd.14601","journal-title":"Brit J Dermatol"},{"issue":"6","key":"3760_CR48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2340\/00015555-3166","volume":"99","author":"O Lindgren","year":"2019","unstructured":"Lindgren O, Varpuluoma O, Tuusa J, Ilonen J, Huilaja L, Kokkonen N, Tasanen K (2019) Gliptin-associated Bullous Pemphigoid and the expression of Dipeptidyl Peptidase-4\/CD26 in Bullous Pemphigoid. Acta Derm Venereol 99(6):602\u2013609. https:\/\/doi.org\/10.2340\/00015555-3166","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"3760_CR49","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","volume":"138","author":"H Ujiie","year":"2018","unstructured":"Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H et al (2018) HLA-DQB1*03:01 as a biomarker for genetic susceptibility to Bullous Pemphigoid Induced by DPP-4 inhibitors. J Invest Dermatol 138(5):1201\u20131204. https:\/\/doi.org\/10.1016\/j.jid.2017.11.023","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3760_CR50","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jdi.14004","volume":"14","author":"Y Harano","year":"2023","unstructured":"Harano Y, Mitamura Y, Jiang P, Fujita T, Babazono A (2023) Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: a population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database. J Diabetes Investig 14(6):756\u2013766. https:\/\/doi.org\/10.1111\/jdi.14004","journal-title":"J Diabetes Investig"},{"issue":"1","key":"3760_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12902-021-00689-7","volume":"21","author":"V Lambadiari","year":"2021","unstructured":"Lambadiari V, Kountouri A, Kousathana F, Korakas E, Kokkalis G, Theotokoglou S et al (2021) The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study. BMC Endocr Disord 21(1):23. https:\/\/doi.org\/10.1186\/s12902-021-00689-7","journal-title":"BMC Endocr Disord"},{"issue":"8","key":"3760_CR52","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","volume":"42","author":"A Douros","year":"2019","unstructured":"Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L (2019) Dipeptidyl Peptidase 4 inhibitors and the risk of Bullous Pemphigoid among patients with type 2 diabetes. Diabetes Care 42(8):1496\u20131503. https:\/\/doi.org\/10.2337\/dc19-0409","journal-title":"Diabetes Care"},{"key":"3760_CR53","doi-asserted-by":"publisher","first-page":"1084960","DOI":"10.3389\/fimmu.2022.1084960","volume":"13","author":"K Nozawa","year":"2023","unstructured":"Nozawa K, Suzuki T, Kayanuma G, Yamamoto H, Nagayasu K, Shirakawa H, Kaneko S (2023) Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the mas receptor pathway. Front Immunol 13:1084960. https:\/\/doi.org\/10.3389\/fimmu.2022.1084960","journal-title":"Front Immunol"},{"key":"3760_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejps.2016.12.040","volume":"100","author":"MM Pinheiro","year":"2017","unstructured":"Pinheiro MM, Stoppa CL, Valduga CJ, Okuyama CE, Gorjao R, Pereira RMS, Diniz SN (2017) Sitagliptin inhibit human lymphocytes proliferation and Thl\/Th17 differentiation in vitro. Eur J Pharm Sci 100:17\u201324. https:\/\/doi.org\/10.1016\/j.ejps.2016.12.040","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"3760_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","volume":"87","author":"A Salemme","year":"2022","unstructured":"Salemme A, Fania L, Scarabello A, Caproni M, Marzano AV, Cozzani E et al (2022) Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: results of a multicenter study. J Am Acad Dermatol 87(1):56\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2022.02.036","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3760_CR56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","volume":"158","author":"JT Said","year":"2022","unstructured":"Said JT, Liu MF, Talia J, Singer SB, Semenov YR, Wei EX et al (2022) Risk factors for the development of Bullous Pemphigoid in US patients receiving Immune Checkpoint inhibitors. Jama Dermatology 158(5):552\u2013557. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0354","journal-title":"Jama Dermatology"},{"issue":"2","key":"3760_CR57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/bjd\/ljae172","volume":"191","author":"K Sarkovics","year":"2024","unstructured":"Sarkovics K, Kolodney JA, Kolodney MS (2024) Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study. Br J Dermatol 191(2):299\u2013300. https:\/\/doi.org\/10.1093\/bjd\/ljae172","journal-title":"Br J Dermatol"},{"key":"3760_CR58","doi-asserted-by":"publisher","first-page":"1068978","DOI":"10.3389\/fimmu.2022.1068978","volume":"13","author":"SS Guan","year":"2023","unstructured":"Guan SS, Zhang LL, Zhang JY, Song WJ, Zhong DS (2023) A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy. Front Immunol 13:1068978. https:\/\/doi.org\/10.3389\/fimmu.2022.1068978","journal-title":"Front Immunol"},{"issue":"6","key":"3760_CR59","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","volume":"2","author":"W Damsky","year":"2016","unstructured":"Damsky W, Kole L, Tomayko MM (2016) Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2(6):442\u2013444. https:\/\/doi.org\/10.1016\/j.jdcr.2016.05.009","journal-title":"JAAD Case Rep"},{"key":"3760_CR60","doi-asserted-by":"publisher","first-page":"1124730","DOI":"10.3389\/fonc.2023.1124730","volume":"13","author":"T Wang","year":"2023","unstructured":"Wang T, Shao QW, Xiao CM, Liu LK (2023) Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR\/MSS colorectal cancer. Front Oncol 13:1124730. https:\/\/doi.org\/10.3389\/fonc.2023.1124730","journal-title":"Front Oncol"},{"issue":"4","key":"3760_CR61","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","volume":"82","author":"OH Ali","year":"2020","unstructured":"Ali OH, Bomze D, Ring SS, Berner F, Fassler M, Diem S et al (2020) BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 82(4):854\u2013861. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.045","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3760_CR62","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/bjd.19313","volume":"183","author":"GE Molina","year":"2020","unstructured":"Molina GE, Reynolds KL, Chen ST (2020) Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross\u2010sectional study. Br J Dermatol 183(6):1126\u20131128. https:\/\/doi.org\/10.1111\/bjd.19313","journal-title":"Br J Dermatol"},{"issue":"8","key":"3760_CR63","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1111\/jdv.19860","volume":"38","author":"N Kramer","year":"2024","unstructured":"Kramer N, M\u00fcller G, Zierold S, R\u00f6ckel M, Fr\u00f6hlich W, Schefzyk M et al (2024) Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid. J Eur Acad Dermatol Venereol 38(8):e722\u2013e728. https:\/\/doi.org\/10.1111\/jdv.19860","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"3760_CR64","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","volume":"33","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed H, Steinhoff M (2022) Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. J Dermatological Treat 33(7):2886\u20132893. https:\/\/doi.org\/10.1080\/09546634.2022.2089331","journal-title":"J Dermatological Treat"},{"issue":"8","key":"3760_CR65","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1365-2230.2011.04102.x","volume":"36","author":"J Kluk","year":"2011","unstructured":"Kluk J, Goulding JMR, Bhat J, Finch TM (2011) Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol 36(8):871\u2013873. https:\/\/doi.org\/10.1111\/j.1365-2230.2011.04102.x","journal-title":"Clin Exp Dermatol"},{"key":"3760_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01053-9","author":"M Croft","year":"2024","unstructured":"Croft M, Salek-Ardakani S, Ware CF (2024) Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov Oct. https:\/\/doi.org\/10.1038\/s41573-024-01053-9.:24","journal-title":"Nat Rev Drug Discov Oct"},{"issue":"1","key":"3760_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1684\/ejd.2018.3431","volume":"29","author":"N Tani","year":"2019","unstructured":"Tani N, Sugita K, Yanagihara S, Yamamoto O (2019) Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis. Eur J Dermatol 29(1):88\u201390. https:\/\/doi.org\/10.1684\/ejd.2018.3431","journal-title":"Eur J Dermatol"},{"issue":"5","key":"3760_CR68","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.crohns.2013.11.018","volume":"8","author":"B Hall","year":"2014","unstructured":"Hall B, Kiely C, Tobin AM, McNamara D (2014) HAHA antibodies \u2014 not such a funny story. J Crohns Colitis 8(5):439\u2013440. https:\/\/doi.org\/10.1016\/j.crohns.2013.11.018","journal-title":"J Crohns Colitis"},{"issue":"6","key":"3760_CR69","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1111\/1346-8138.16711","volume":"50","author":"N Sugihara","year":"2023","unstructured":"Sugihara N, Kamiya K, Nakano N, Suzuki M, Maekawa T, Murata S et al (2023) A case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris. J Dermatol 50(6):E185\u2013E186. https:\/\/doi.org\/10.1111\/1346-8138.16711","journal-title":"J Dermatol"},{"issue":"7","key":"3760_CR70","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/1346-8138.16765","volume":"50","author":"R Wang","year":"2023","unstructured":"Wang R, Wang AP, Wang MY (2023) Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: a paradoxical reaction. J Dermatol 50(7):956\u2013959. https:\/\/doi.org\/10.1111\/1346-8138.16765","journal-title":"J Dermatol"},{"issue":"9","key":"3760_CR71","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1111\/1346-8138.13909","volume":"44","author":"PH Ho","year":"2017","unstructured":"Ho PH, Tsai TF (2017) Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol 44(9):e220\u2013e221. https:\/\/doi.org\/10.1111\/1346-8138.13909","journal-title":"J Dermatol"},{"key":"3760_CR72","doi-asserted-by":"publisher","first-page":"n","DOI":"10.5580\/867","volume":"14","author":"DJ Yang","year":"2006","unstructured":"Yang DJ, Brownell I, Duvic M (2006) Celecoxib-Induced Bullous Pemphigoid: report of the First Case. Internet J Anesthesiol 14:n. https:\/\/doi.org\/10.5580\/867","journal-title":"Internet J Anesthesiol"},{"issue":"2","key":"3760_CR73","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000051744","volume":"203","author":"M Vaccaro","year":"2001","unstructured":"Vaccaro M, D\u2019Amico D, Borgia F, Guarneri F, Cannavo SP (2001) Bullous pemphigoid following use of sulphasalazine for ulcerative colitis: drug-induced eruption or true association? Dermatology 203(2):194\u2013195. https:\/\/doi.org\/10.1159\/000051744","journal-title":"Dermatology"},{"issue":"9","key":"3760_CR74","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1001\/archderm.120.9.1196","volume":"120","author":"M Kashihara","year":"1984","unstructured":"Kashihara M, Danno K, Miyachi Y, Horiguchi Y, Imamura S (1984) Bullous pemphigoid-like lesions induced by phenacetin-report of a case and an immunopathologic study. Arch Dermatol 120(9):1196\u20131199. https:\/\/doi.org\/10.1001\/archderm.120.9.1196","journal-title":"Arch Dermatol"},{"issue":"11","key":"3760_CR75","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1111\/bcp.13737","volume":"84","author":"RA Ballout","year":"2018","unstructured":"Ballout RA, Musharrafieh U, Khattar J (2018) Lisinopril-associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction. Br J Clin Pharmacol 84(11):2678\u20132682. https:\/\/doi.org\/10.1111\/bcp.13737","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3760_CR76","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","volume":"81","author":"O Varpuluoma","year":"2019","unstructured":"Varpuluoma O, Jokelainen J, Forsti AK, Turpeinen M, Timonen M, Huilaja L, Tasanen K (2019) Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case-control study. JEADV 81(1):250\u2013253. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.017","journal-title":"JEADV"},{"issue":"8","key":"3760_CR77","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","volume":"156","author":"SD Liu","year":"2020","unstructured":"Liu SD, Chen WT, Chi CC (2020) Association between Medication Use and Bullous Pemphigoid: a systematic review and Meta-analysis. JAMA Dermatol 156(8):891\u2013900. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1587","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3760_CR78","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12888-020-02810-x","volume":"20","author":"M Rania","year":"2020","unstructured":"Rania M, Petersen LV, Benros ME, Liu Z, Diaz L, Bulik CM (2020) Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers. BMC Psychiatry 20(1):411. https:\/\/doi.org\/10.1186\/s12888-020-02810-x","journal-title":"BMC Psychiatry"},{"issue":"8","key":"3760_CR79","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/jdv.12662","volume":"29","author":"L Atzori","year":"2015","unstructured":"Atzori L, Conti B, Zucca M, Pau M (2015) Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients. J Eur Acad Dermatol Venereol 29(8):1626\u20131630. https:\/\/doi.org\/10.1111\/jdv.12662","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3760_CR80","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.jaad.2012.01.034","volume":"67","author":"L Stingeni","year":"2012","unstructured":"Stingeni L, Bianchi L, Minotti V, Lisi P (2012) Erlotinib-induced bullous pemphigoid. J Am Acad Dermatol 67:e199\u2013e201. https:\/\/doi.org\/10.1016\/j.jaad.2012.01.034","journal-title":"J Am Acad Dermatol"},{"key":"3760_CR81","doi-asserted-by":"publisher","first-page":"2050313X2311642","DOI":"10.1177\/2050313X231164222","volume":"11","author":"HO-Y Li","year":"2023","unstructured":"Li HO-Y, Aw M, Glassman SJ (2023) Imiquimod-induced bullous pemphigoid: a case report. SAGE Open Med Case Rep 11:2050313X231164222. https:\/\/doi.org\/10.1177\/2050313X231164222","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"3760_CR82","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1046\/j.1365-2133.1998.02097.x","volume":"138","author":"AMR Downs","year":"1998","unstructured":"Downs AMR, Lear JT, Bower CPR, Kennedy CTC (1998) Does influenza vaccination induce bullous pemphigoid? A report of four cases. Brit J Dermatol 138(2):363\u2013363. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02097.x","journal-title":"Brit J Dermatol"},{"key":"3760_CR83","doi-asserted-by":"publisher","first-page":"1112823","DOI":"10.3389\/fmed.2023.1112823","volume":"10","author":"A Pira","year":"2023","unstructured":"Pira A, Sinagra JLM, Moro F, Mariotti F, Di Zenzo G (2023) Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on Rituximab and vaccine. Front Med 10:1112823. https:\/\/doi.org\/10.3389\/fmed.2023.1112823","journal-title":"Front Med"},{"key":"3760_CR84","doi-asserted-by":"publisher","first-page":"1117176","DOI":"10.3389\/fmed.2022.1117176","volume":"9","author":"TL Cowan","year":"2022","unstructured":"Cowan TL, Huang C, Murrell DF (2022) Autoimmune blistering skin diseases triggered by COVID-19 vaccinations: an Australian case series. Front Med (Lausanne) 9:1117176. https:\/\/doi.org\/10.3389\/fmed.2022.1117176","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3760_CR85","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.4081\/dr.2021.9170","volume":"14","author":"A Piras","year":"2021","unstructured":"Piras A, Fionda B, Sanfratello A, D\u2019Aviero A, Sortino G, Pernice G et al (2021) Bullous pemphigoid and radiotherapy: case report and literature review update. Dermatol Rep 14(2):9170. https:\/\/doi.org\/10.4081\/dr.2021.9170","journal-title":"Dermatol Rep"},{"issue":"2","key":"3760_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdermsci.2022.12.001","volume":"108","author":"K Kogawa","year":"2022","unstructured":"Kogawa K, Matsuzaki Y, Kimura A, Minakawa S, Nakano H, Ito K et al (2022) Ultraviolet B irradiation leads to the development of experimental bullous pemphigoid targeting BPAG1e. J Dermatol Sci 108(2):112\u2013115. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.12.001","journal-title":"J Dermatol Sci"},{"issue":"1","key":"3760_CR87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-019-01985-y","volume":"312","author":"TL Hung","year":"2020","unstructured":"Hung TL, Chen YL, Lin KT, Chiang CP, Chung CH, Hung CT et al (2020) Risk of radiotherapy-associated autoimmune bullous disease among Taiwanese patients with breast cancer: a case-control study. Arch Dermatol Res 312(1):69\u201375. https:\/\/doi.org\/10.1007\/s00403-019-01985-y","journal-title":"Arch Dermatol Res"},{"key":"3760_CR88","doi-asserted-by":"publisher","first-page":"104290","DOI":"10.1016\/j.pdpdt.2024.104290","volume":"49","author":"L Shi","year":"2024","unstructured":"Shi L, Zhang F, Yan J, Luo M, Liu K, Liu P et al (2024) Photothermal therapy improves the efficacy of topical immunotherapy against melanoma. Photodiagnosis Photodyn Ther 49:104290. https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104290","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"1","key":"3760_CR89","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/0886022x.2021.1910045","volume":"43","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yoshida T, Washida N, Uchiyama K, Nakayama T, Itoh H, Oya M (2021) Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey. Ren Fail 43(1):651\u2013657. https:\/\/doi.org\/10.1080\/0886022x.2021.1910045","journal-title":"Ren Fail"},{"issue":"12","key":"3760_CR90","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/1346-8138.16948","volume":"50","author":"CH Tang","year":"2023","unstructured":"Tang CH, Sue YM, Chang CL, Wang CC (2023) Risk of bullous pemphigoid and pemphigus in patients on chronic dialysis: a nationwide population-based cohort study. J Dermatol 50(12):1568\u20131575. https:\/\/doi.org\/10.1111\/1346-8138.16948","journal-title":"J Dermatol"},{"key":"3760_CR91","doi-asserted-by":"publisher","first-page":"1160779","DOI":"10.3389\/fimmu.2023.1160779","volume":"14","author":"L Corbella-Bagot","year":"2023","unstructured":"Corbella-Bagot L, Gil-Lianes J, Fernandez-Vela J, Marif-Marti I, Alegre-Fernandez M, Fuertes I et al (2023) Case Report: localized bullous pemphigoid induced by local triggers: a case series and a proposal for diagnostic criteria based on a literature review. Front Immunol 14:1160779. https:\/\/doi.org\/10.3389\/fimmu.2023.1160779","journal-title":"Front Immunol"},{"issue":"3","key":"3760_CR92","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1111\/jdv.19548","volume":"38","author":"M Kasperkiewicz","year":"2023","unstructured":"Kasperkiewicz M, Kupiec-Weglinski JW, Ngo BT, Kridin K, Ludwig RJ (2023) Risk of de novo bullous pemphigoid and pemphigus following transplantation: a global wide-scale cohort study. J Eur Acad Dermatol 38(3):e231\u2013e233. https:\/\/doi.org\/10.1111\/jdv.19548","journal-title":"J Eur Acad Dermatol"},{"issue":"10","key":"3760_CR93","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/jdv.17304","volume":"35","author":"S Stander","year":"2021","unstructured":"Stander S, Hammers CM, Vorobyev A, Schmidt E, Hundt JE, Sadik CD et al (2021) Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-BP230 seropositivity. JEADV 35(10):2067\u20132073. https:\/\/doi.org\/10.1111\/jdv.17304","journal-title":"JEADV"},{"issue":"11","key":"3760_CR94","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/brainsci11111386","volume":"11","author":"M Fabrazzo","year":"2021","unstructured":"Fabrazzo M, Boccardi M, Cipolla S, Galiero R, Tucci C, Perris F et al (2021) Bipolar patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: a Case Report and a review of the literature. Brain Sci 11(11):1386. https:\/\/doi.org\/10.3390\/brainsci11111386","journal-title":"Brain Sci"},{"issue":"5","key":"3760_CR95","doi-asserted-by":"publisher","first-page":"637","DOI":"10.17219\/acem\/90922","volume":"28","author":"A Kalinska-Bienias","year":"2019","unstructured":"Kalinska-Bienias A, Kowalczyk E, Jagielski P, Bienias P, Kowalewski C, Wozniak K (2019) The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: case-control study in a specialized Polish center. Adv Clin Exp Med 28(5):637\u2013642. https:\/\/doi.org\/10.17219\/acem\/90922","journal-title":"Adv Clin Exp Med"},{"key":"3760_CR96","doi-asserted-by":"publisher","first-page":"1196999","DOI":"10.3389\/fimmu.2023.1196999","volume":"14","author":"J Huttelmaier","year":"2023","unstructured":"Huttelmaier J, Benoit S, Goebeler M (2023) Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol 14:1196999. https:\/\/doi.org\/10.3389\/fimmu.2023.1196999","journal-title":"Front Immunol"},{"issue":"6","key":"3760_CR97","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bjd.15405","volume":"176","author":"L Kibsgaard","year":"2017","unstructured":"Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C (2017) Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol 176(6):1486\u20131491. https:\/\/doi.org\/10.1111\/bjd.15405","journal-title":"Br J Dermatol"},{"issue":"1","key":"3760_CR98","doi-asserted-by":"publisher","first-page":"e14869","DOI":"10.1111\/exd.14869","volume":"33","author":"S Shen","year":"2024","unstructured":"Shen S, Chu M, Miao H, Li L, Fang H, Li X et al (2024) Assessment of relationships between bullous pemphigoid and neurological diseases: a bidirectional two-sample mendelian randomization study. Exp Dermatol 33(1):e14869. https:\/\/doi.org\/10.1111\/exd.14869","journal-title":"Exp Dermatol"},{"issue":"5","key":"3760_CR99","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s12026-018-9028-1","volume":"66","author":"TA Julio","year":"2018","unstructured":"Julio TA, Vernal S, Massaro JD, Silva MC, Donadi EA, Moriguti JC, Roselino AM (2018) Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180\/BP230 brain and skin isoforms. Immunol Res 66(5):567\u2013576. https:\/\/doi.org\/10.1007\/s12026-018-9028-1","journal-title":"Immunol Res"},{"issue":"2","key":"3760_CR100","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2017.02.057","volume":"77","author":"K Kridin","year":"2017","unstructured":"Kridin K, Bergman R (2017) Association between bullous pemphigoid and psoriasis: a case-control study. J Am Acad Dermatol 77(2):370\u2013372. https:\/\/doi.org\/10.1016\/j.jaad.2017.02.057","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"3760_CR101","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1365-4632.2006.02861.x","volume":"45","author":"A Wilczek","year":"2006","unstructured":"Wilczek A, Sticherling M (2006) Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship? Int J Dermatol 45(11):1353\u20131357. https:\/\/doi.org\/10.1111\/j.1365-4632.2006.02861.x","journal-title":"Int J Dermatol"},{"key":"3760_CR102","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fmed.2020.00511","volume":"7","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ludwig RJ, Schonmann Y, Damiani G, Cohen AD (2020) The Bidirectional Association between Bullous Pemphigoid and Psoriasis: a Population-based Cohort Study. Front Med 7:511. https:\/\/doi.org\/10.3389\/fmed.2020.00511","journal-title":"Front Med"},{"key":"3760_CR103","doi-asserted-by":"publisher","first-page":"1365118","DOI":"10.3389\/fimmu.2024.1365118","volume":"15","author":"A Zhang","year":"2024","unstructured":"Zhang A, Yang Z, Huang T, Wang M (2024) Causal association between psoriasis vulgaris and bullous pemphigoid: a two-sample bidirectional mendelian randomization study. Front Immunol 15:1365118. https:\/\/doi.org\/10.3389\/fimmu.2024.1365118","journal-title":"Front Immunol"},{"issue":"4","key":"3760_CR104","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/jdv.17013","volume":"35","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S, Schmidt E, Zillikens D, Tha\u00e7i D, Ludwig R, Kridin K (2021) Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. JEADV 35(4):981\u2013987. https:\/\/doi.org\/10.1111\/jdv.17013","journal-title":"JEADV"},{"issue":"3","key":"3760_CR105","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00403-022-02372-w","volume":"315","author":"PC Wu","year":"2023","unstructured":"Wu PC, Wu CY, Lyu YS, Chang YT, Wu CY (2023) Association between bullous pemphigoid and atopic dermatitis: a population-based case-control study in Taiwan. Arch Dermatol Res 315(3):419\u2013427. https:\/\/doi.org\/10.1007\/s00403-022-02372-w","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"3760_CR106","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/der.0000000000000792","volume":"33","author":"K Kridin","year":"2022","unstructured":"Kridin K, Hammers CM, Ludwig RJ, Onn E, Schonmann Y, Abu-Elhija A et al (2022) The Association of Bullous Pemphigoid with atopic dermatitis and allergic Rhinitis-A Population-based study. Dermatitis 33(4):268\u2013276. https:\/\/doi.org\/10.1097\/der.0000000000000792","journal-title":"Dermatitis"},{"issue":"1","key":"3760_CR107","doi-asserted-by":"publisher","first-page":"12727","DOI":"10.1038\/s41598-020-69475-0","volume":"10","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Juan CK, Chang YT, Wu CY, Ho HJ, Tseng HC (2020) Association between inflammatory bowel disease and bullous pemphigoid: a population-based case-control study. Sci Rep 10(1):12727. https:\/\/doi.org\/10.1038\/s41598-020-69475-0","journal-title":"Sci Rep"},{"issue":"6","key":"3760_CR108","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1159\/000512917","volume":"237","author":"K Kridin","year":"2021","unstructured":"Kridin K, Ludwig RJ, Bitan DT, Cohen AD (2021) A history of Asthma increases the risk of Bullous Pemphigoid: insights from a large Population-based study. Dermatology 237(6):921\u2013928. https:\/\/doi.org\/10.1159\/000512917","journal-title":"Dermatology"},{"issue":"6","key":"3760_CR109","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/00015550510034146","volume":"85","author":"MC Fiorucci","year":"2005","unstructured":"Fiorucci MC, Cozzani E, Casu M, Murialdo G, Parodi A, Rebora A (2005) Bullous pemphigoid and Graves\u2019 disease: an association between skin and thyroid autoimmunity. Acta Derm Venereol 85(6):560\u2013561. https:\/\/doi.org\/10.1080\/00015550510034146","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"3760_CR110","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/cup.14206","volume":"49","author":"CBC Cobb","year":"2022","unstructured":"Cobb CBC, Caravaglio JV, Qureshi AA, Robinson-Bostom L (2022) Concominant bullous pemphigoid and cutaneous Crohn disease. J Cutan Pathol 49(6):579\u2013583. https:\/\/doi.org\/10.1111\/cup.14206","journal-title":"J Cutan Pathol"},{"issue":"5","key":"3760_CR111","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1046\/j.1365-2133.1998.02534.x","volume":"139","author":"F Loche","year":"1998","unstructured":"Loche F, Bernard P, Bazex J (1998) Bullous pemphigoid associated with systemic lupus erythematosus. Br J Dermatol 139(5):927\u2013928. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02534.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"3760_CR112","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/bf02944199","volume":"166","author":"SM Sant","year":"1997","unstructured":"Sant SM, O\u2019Loughlin S, Murphy GM (1997) Bullous pemphigoid and rheumatoid arthritis: is there disease association? Ir J Med Sci 166(2):106\u2013107. https:\/\/doi.org\/10.1007\/bf02944199","journal-title":"Ir J Med Sci"},{"issue":"6100","key":"3760_CR113","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1136\/bmj.2.6100.1458-a","volume":"2","author":"OE Obasi","year":"1977","unstructured":"Obasi OE, Savin JA (1977) Pemphigoid and pernicious anaemia. Br Med J 2(6100):1458\u20131459. https:\/\/doi.org\/10.1136\/bmj.2.6100.1458-a","journal-title":"Br Med J"},{"issue":"2","key":"3760_CR114","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.jaad.2018.02.080","volume":"79","author":"S Geller","year":"2018","unstructured":"Geller S, Kremer N, Zeeli T, Sprecher E (2018) Bullous pemphigoid and diabetes mellitus: are we missing the larger picture? J Am Acad Dermatol 79(2):e27. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.080","journal-title":"J Am Acad Dermatol"},{"key":"3760_CR115","doi-asserted-by":"publisher","first-page":"825796","DOI":"10.3389\/fimmu.2022.825796","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Zhan S, Hua C, Tang Y, Cheng H (2022) A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated with Pulmonary Tuberculosis: a Case Report and the RNA-seq analysis. Front Immunol 13:825796. https:\/\/doi.org\/10.3389\/fimmu.2022.825796","journal-title":"Front Immunol"},{"issue":"2","key":"3760_CR116","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23812\/j.biol.regul.homeost.agents.202236.2S4.3","volume":"36","author":"A Lucchese","year":"2022","unstructured":"Lucchese A, Di Stasio D, Borgia R, Scivetti M, Petruzzi M (2022) Peptide sharing between SARS-CoV-2 and Bullous pemphigoid 180. J Biol Reg Homeos Ag 36(2):13\u201318. https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.202236.2S4.3","journal-title":"J Biol Reg Homeos Ag"},{"issue":"9","key":"3760_CR117","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1111\/all.16210","volume":"79","author":"B Kratzer","year":"2024","unstructured":"Kratzer B, Gattinger P, Trapin D, Ettel P, K\u00f6rm\u00f6czi U, Rottal A et al (2024) Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1\/inflammatory to Th2 serum cytokine levels long after first COVID-19. Allergy 79(9):2482\u20132501. https:\/\/doi.org\/10.1111\/all.16210","journal-title":"Allergy"},{"issue":"11","key":"3760_CR118","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/1756-185x.14875","volume":"26","author":"A Mosavat","year":"2023","unstructured":"Mosavat A, Mirhosseini A, Shariati A, Mohareri M, Valizadeh N, Mohammadi FS et al (2023) SARS-CoV-2 infection and increasing autoimmune disorders among ICU-hospitalized COVID-19 patients. Int J Rheum Dis 26(11):2151\u20132156. https:\/\/doi.org\/10.1111\/1756-185x.14875","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"3760_CR119","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.autrev.2020.102661","volume":"19","author":"H Fang","year":"2020","unstructured":"Fang H, Li QY, Wang G (2020) The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun Rev 19(11):102661. https:\/\/doi.org\/10.1016\/j.autrev.2020.102661","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3760_CR120","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu T, Wang Z, Xue X, Wang Z, Zhang Y, Mi Z et al (2024) Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease. Nat Commun 15(1):5949. https:\/\/doi.org\/10.1038\/s41467-024-50283-3","journal-title":"Nat Commun"},{"issue":"4","key":"3760_CR121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3315\/jdcr.2011.1081","volume":"5","author":"N Walmsley","year":"2011","unstructured":"Walmsley N, Hampton P (2011) Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid. J Dermatol Case Rep 5(4):74\u201376. https:\/\/doi.org\/10.3315\/jdcr.2011.1081","journal-title":"J Dermatol Case Rep"},{"issue":"11","key":"3760_CR122","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/jid.2011.180","volume":"131","author":"G Di Zenzo","year":"2011","unstructured":"Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP et al (2011) Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: results of a prospective Multicenter Study. J Invest Dermatol 131(11):2271\u20132280. https:\/\/doi.org\/10.1038\/jid.2011.180","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3760_CR123","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jid.2020.08.031","volume":"141","author":"E Makita","year":"2021","unstructured":"Makita E, Matsuzaki Y, Fukui T, Matsui A, Minakawa S, Nakano H et al (2021) Autoantibodies to BPAG1e trigger experimental Bullous Pemphigoid in mice. J Invest Dermatol 141(5):1167\u20131176e1163. https:\/\/doi.org\/10.1016\/j.jid.2020.08.031","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3760_CR124","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","volume":"138","author":"L Lin","year":"2018","unstructured":"Lin L, Hwang B, Culton DA, Li N, Burette S, Koller BH et al (2018) Eosinophils Mediate Tissue Injury in the autoimmune skin Disease Bullous Pemphigoid. J Invest Dermatol 138(5):1032\u20131043. https:\/\/doi.org\/10.1016\/j.jid.2017.11.031","journal-title":"J Invest Dermatol"},{"key":"3760_CR125","doi-asserted-by":"publisher","first-page":"912876","DOI":"10.3389\/fimmu.2022.912876","volume":"13","author":"C Cole","year":"2022","unstructured":"Cole C, Vinay K, Borradori L, Amber KT (2022) Insights into the pathogenesis of Bullous Pemphigoid: the role of complement-independent mechanisms. Front Immunol 13:912876. https:\/\/doi.org\/10.3389\/fimmu.2022.912876","journal-title":"Front Immunol"},{"issue":"11","key":"3760_CR126","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","volume":"127","author":"JA Fairley","year":"2007","unstructured":"Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ (2007) A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice. J Invest Dermatol 127(11):2605\u20132611. https:\/\/doi.org\/10.1038\/sj.jid.5700958","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3760_CR127","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","volume":"127","author":"JJ Zone","year":"2007","unstructured":"Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L (2007) IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 127(5):1167\u20131174. https:\/\/doi.org\/10.1038\/sj.jid.5700681","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3760_CR128","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hyb.2011.0102","volume":"31","author":"KA Messingham","year":"2012","unstructured":"Messingham KA, Onoh A, Vanderah EM, Giudice GJ, Fairley JA (2012) Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180. Hybrid (Larchmt) 31(2):111\u2013117. https:\/\/doi.org\/10.1089\/hyb.2011.0102","journal-title":"Hybrid (Larchmt)"},{"issue":"3","key":"3760_CR129","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","volume":"123","author":"JA Fairley","year":"2009","unstructured":"Fairley JA, Baum CL, Brandt DS, Messingham KA (2009) Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 123(3):704\u2013705. https:\/\/doi.org\/10.1016\/j.jaci.2008.11.035","journal-title":"J Allergy Clin Immunol"},{"key":"3760_CR130","doi-asserted-by":"publisher","first-page":"611549","DOI":"10.3389\/fimmu.2020.611549","volume":"11","author":"SM Seyed Jafari","year":"2020","unstructured":"Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L (2020) Case Report: combination of Omalizumab and Dupilumab for recalcitrant Bullous Pemphigoid. Front Immunol 11:611549. https:\/\/doi.org\/10.3389\/fimmu.2020.611549","journal-title":"Front Immunol"},{"key":"3760_CR131","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","volume":"8","author":"YL Liu","year":"2017","unstructured":"Liu YL, Li L, Xia YM (2017) BP180 is critical in the autoimmunity of Bullous Pemphigoid. Front Immunol 8:1752. https:\/\/doi.org\/10.3389\/fimmu.2017.01752","journal-title":"Front Immunol"},{"issue":"2","key":"3760_CR132","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2020.05.010","volume":"100","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang G (2020) Genetic predisposition to bullous pemphigoid. J Dermatol Sci 100(2):86\u201391. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.05.010","journal-title":"J Dermatol Sci"},{"key":"3760_CR133","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","volume":"2017","author":"K Juczynska","year":"2017","unstructured":"Juczynska K, Wozniacka A, Waszczykowska E, Danilewicz M, Wagrowska-Danilewicz M, Wieczfinska J et al (2017) Expression of the JAK\/STAT signaling pathway in Bullous Pemphigoid and Dermatitis Herpetiformis. Mediat Inflamm 2017:6716419. https:\/\/doi.org\/10.1155\/2017\/6716419","journal-title":"Mediat Inflamm"},{"issue":"7","key":"3760_CR134","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.4049\/jimmunol.169.7.3987","volume":"169","author":"R Chen","year":"2002","unstructured":"Chen R, Fairley JA, Zhao ML, Giudice GJ, Zillikens D, Diaz LA, Liu Z (2002) Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 169(7):3987\u20133992. https:\/\/doi.org\/10.4049\/jimmunol.169.7.3987","journal-title":"J Immunol"},{"issue":"7","key":"3760_CR135","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA (2021) JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80(7):865\u2013875. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3760_CR136","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2249.2011.04391.x","volume":"165","author":"AV Marzano","year":"2011","unstructured":"Marzano AV, Tedeschi A, Berti E, Fanoni D, Crosti C, Cugno M (2011) Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Dermatol 165(1):44\u201350. https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04391.x","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"3760_CR137","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jid.2023.01.029","volume":"143","author":"A Lamberts","year":"2023","unstructured":"Lamberts A, Kotnik N, Meijer JM, van Kempen LC, Diercks GFH, Horv\u00e1th B (2023) Gene expression profiling suggests that complement activation is important for blister formation in Bullous Pemphigoid. J Invest Dermatol 143(8):1591\u20131594e1592. https:\/\/doi.org\/10.1016\/j.jid.2023.01.029","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3760_CR138","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/path.6220","volume":"262","author":"M Pigors","year":"2024","unstructured":"Pigors M, Patzelt S, Reichhelm N, Dworschak J, Khil\u2019chenko S, Emtenani S et al (2024) Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal fc receptor blockade. J Pathol 262(2):161\u2013174. https:\/\/doi.org\/10.1002\/path.6220","journal-title":"J Pathol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03760-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:59:59Z","timestamp":1737727199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03760-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":138,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3760"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03760-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}